Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
about
Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesClinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosisQuantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemiaRevised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090Splanchnic vein thrombosis in myeloproliferative neoplasms.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasmsMolecular diagnostics of myeloproliferative neoplasms.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyMolecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasmsAssessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.Clinical and laboratory assessment of a patient with thrombocytosis.Serum ferritin as a biomarker of polycythemia vera?The germline mutations of the CHEK2 gene are associated with an increased risk of polycythaemia vera.Incidental abnormal bone marrow signal on magnetic resonance imaging and reflexive testing for the V617F mutationQuantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of V617F mutant allele burdens
P2860
Q28076096-6441E42C-BF31-447D-BA9A-647BB58DA5C6Q28389100-9579E761-57AB-4345-B1EB-35C3B765B0D3Q34687245-97FB00B6-962F-4FA7-A12D-328052830BBEQ35088483-22E2281C-FAE3-4BBF-9823-F988F81FDB37Q35548472-BA8B0871-34CD-49DE-8D9C-9735CCF87417Q36169641-18ACFF59-781C-4BDF-9A2C-BEBBEEF0E62EQ36548080-1346E30D-1E3C-4059-85B4-EA4C90B0CA1AQ36907860-0E0F29CB-0EC4-409D-B8E9-BFFE91634A98Q37067712-357F62CC-2B5F-415E-9648-EC665E8830B3Q37250169-4B7D63BF-4855-4F96-96EE-36D6B8D66F27Q38121635-F1883202-41A3-4042-843B-9B21D32EAEC4Q38132817-3CD9650E-9DCA-4333-8CEC-B483E8AC846CQ38265111-B688B8F8-E853-4AEE-9B89-A751661FFD68Q38464571-40519F0E-02EA-4DE7-9506-A1F8D9720EA2Q38816384-2E57E250-B407-447D-AF87-9D8F088F1F97Q38830536-3B887D98-C74E-4A02-848A-5EAD0AC60D44Q38978004-38376144-B17F-41A5-9FA7-30A80F81C115Q39309957-EB38D06A-092E-4692-8186-1D1BB9912180Q40202920-35FAAB1F-E8B1-4AD6-A86A-947D4954913AQ41911563-37E0EA99-258D-4DE4-BB76-C859B4F93ECEQ42062133-EE8DAF1E-FE98-4D87-9F20-3D917370B9DDQ42671679-A8B447F7-620C-4369-842A-33D9A9FF151BQ47353004-C8CCB790-AE79-438A-B451-B6F4A1A6984AQ50093425-E6BCAB86-C837-40FE-ADAE-54F76740DB59Q55017135-DDFD2552-8091-4A0F-AE9E-18DCDBAD0013Q55056089-32B51B2B-C08E-4A32-B85D-C8BD161A5732Q57300746-6153AD72-0882-4B0F-8CD8-5101F4D3030DQ58793774-15DD78E7-CA86-49BF-85D3-E5B678979A4A
P2860
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Molecular diagnosis of the mye ...... and other relevant mutations.
@en
Molecular diagnosis of the mye ...... and other relevant mutations.
@nl
type
label
Molecular diagnosis of the mye ...... and other relevant mutations.
@en
Molecular diagnosis of the mye ...... and other relevant mutations.
@nl
prefLabel
Molecular diagnosis of the mye ...... and other relevant mutations.
@en
Molecular diagnosis of the mye ...... and other relevant mutations.
@nl
P2093
P2860
P50
P356
P1476
Molecular diagnosis of the mye ...... and other relevant mutations.
@en
P2093
Abida Awan
Andrea Goday-Fernandez
Anna L Godfrey
Anna Schuh
Anthony J Bench
Anthony R Green
Claire N Harrison
David Grimwade
Helen E White
Ian Carter
P2860
P356
10.1111/BJH.12075
P407
P577
2012-10-11T00:00:00Z